Vivimed Labs logo

Vivimed Labs share news, announcements and annual reports

NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap

Vivimed Labs Limited · Face value ₹2 · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)

Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.

30 Oct: open ₹5.62, high ₹5.64, low ₹5.53

Market cap
₹46 Cr3,293rd largest listed
P/E
No recent results
P/B
No recent results
Dividend yield
Nonein the last 12 months
Volume, NSE
3,267

Vivimed Labs board meetings

142 filed, newest first. Page 2 of 3.

  1. Nov 2019

  2. Jul 2019

  3. May 2019

  4. Feb 2019

  5. Nov 2018

  6. Aug 2018

  7. May 2018

  8. Mar 2018

  9. Jan 2018

  10. Nov 2017

  11. Sep 2017

  12. Aug 2017

  13. Jul 2017

  14. May 2017

  15. Feb 2017

  16. Jan 2017

  17. Oct 2016

  18. Jul 2016

  19. May 2016

  20. Feb 2016

  21. Jan 2016

  22. Dec 2015

  23. Oct 2015

  24. Sep 2015

  25. Aug 2015

  26. Jun 2015

  27. May 2015

  28. Feb 2015

  29. Nov 2014

  30. Oct 2014

    • 31 Oct · Board meeting

      Inter alia, to consider and approve the Un-audited Financial Results of the Company for the Quarter & Half year ended September 30, 2014.

  31. Aug 2014

  32. May 2014

    • 19 May · Board meeting

      Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2014, and recommend dividend, if any, for the financial year 2013-14. In view of this, the Trading Window shall, pursuant to the Code of Conduct for prevention of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 1992, remain closed from May 21, 2014 to May 29, 2014 (both days inclusive) and shall reopen after the expiry of 24 hours after the public announcement of audited financial results is made.

  33. Feb 2014

    • 3 Feb · Board meeting

      Inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter & Nine Months ended December 31, 2013.

  34. Nov 2013

    • 5 Nov · Board meeting

      Inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter & Half year ended September 30, 2013.

  35. Aug 2013

  36. May 2013

    • 16 May · Board meeting

      To consider the Appointment of Dr. V. Peesapati as an Additional Director (Non Executive & Independent) of the Company.

    • 15 May · Board meeting

      Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 24,2013 Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013, and recommend dividend, if any, for the financial year 2012-13.. The Company has now informed the Exchange that due to delay in finalization of account and completion of audit, the aforesaid Board Meeting has been postponed and a meeting of the Board of Directors of the Company will be held on May 30, 2013.

    • 14 May · Board meeting

      Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013, and recommend dividend, if any, for the financial year 2012-13.

  37. Apr 2013

    • 22 Apr · Board meeting

      Board of Directors, vide a Circular Resolution dated April 12, 2013 has approved/declared the payment of Pro Rata Dividend on 6,70,000 Compulsorily convertible and Cumulative preference shares (CCPS) (to the then Preference share holder "NYLIM Jacob Ballas India FUND lll,LLC" as per the terms of CCPS) due to its conversion as Equity shares on March 22, 2013.

  38. Feb 2013